NECTIN4 and breast cancer: Current advances in monoclonal antibody treatment allowed for an anti-nectin-4 antibody (Enfortumab vedotin) to be approved for BC therapy, as moderate to strong overexpression of PVRL4 has been observed in 60% of BC patients [77].